Rational Target Selection & Combinatorial Design Driving Early Clinical Responses Beyond Antibody-Only Therapies
- Combining a CD28-targeting antibody with a complementary non-antibody modality to enable synergistic mechanisms beyond antibody-only approaches and unlock enhanced functional activity
- Applying preclinically driven target selection and a rational combinatorial strategy to increase biological relevance and strengthen translational confidence from bench to patient
- Evaluating early experimental patient data, including emerging complete responses, to provide real-world validation of the therapeutic concept and inform future clinical development